Universal Vision Biotechnology Co Ltd (TWO:3218) — Stock Price
Universal Vision Biotechnology Co Ltd (TWO:3218) is currently trading at NT$145.00 TWD, up 1.75% today. Over the past 52 weeks, shares have ranged between NT$123.50 and NT$206.50. This page tracks Universal Vision Biotechnology Co Ltd's live share price on the TWO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Universal Vision Biotechnology Co Ltd stock valuation.
Universal Vision Biotechnology Co Ltd (3218) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Universal Vision Biotechnology Co Ltd's daily closing share price and trading volume on the TWO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Universal Vision Biotechnology Co Ltd Income Statement — Revenue, Profit & Earnings by Year
Universal Vision Biotechnology Co Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | NT$4.20 Billion | NT$4.23 Billion | NT$4.08 Billion | NT$3.49 Billion | NT$2.63 Billion |
| Cost of Revenue | NT$1.72 Billion | NT$1.70 Billion | NT$1.63 Billion | NT$1.35 Billion | NT$995.36 Million |
| Gross Profit | NT$2.48 Billion | NT$2.53 Billion | NT$2.45 Billion | NT$2.14 Billion | NT$1.64 Billion |
| Research & Development | — | — | — | — | — |
| SG&A | NT$1.11 Billion | NT$1.13 Billion | NT$427.67 Million | NT$398.40 Million | NT$314.04 Million |
| Total Operating Expenses | NT$2.83 Billion | NT$2.83 Billion | NT$1.13 Billion | NT$1.05 Billion | NT$867.59 Million |
| Operating Income | NT$1.38 Billion | NT$1.40 Billion | NT$1.34 Billion | NT$1.11 Billion | NT$776.59 Million |
| EBITDA | — | — | NT$1.78 Billion | NT$1.49 Billion | NT$1.10 Billion |
| EBIT | — | — | NT$1.34 Billion | NT$1.11 Billion | NT$776.59 Million |
| Interest Expense | NT$24.85 Million | NT$20.95 Million | NT$15.83 Million | NT$13.56 Million | NT$13.16 Million |
| Income Before Tax | NT$1.35 Billion | NT$1.32 Billion | NT$1.32 Billion | NT$1.09 Billion | NT$763.11 Million |
| Income Tax Expense | — | — | NT$254.56 Million | NT$223.98 Million | NT$152.45 Million |
| Net Income | NT$1.04 Billion | NT$1.06 Billion | NT$1.05 Billion | NT$850.53 Million | NT$595.43 Million |
Universal Vision Biotechnology Co Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Universal Vision Biotechnology Co Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | NT$6.09 Billion | NT$5.76 Billion | NT$5.13 Billion | NT$4.51 Billion | NT$3.75 Billion |
| Total Current Assets | NT$3.00 Billion | NT$2.84 Billion | NT$2.58 Billion | NT$2.16 Billion | NT$1.78 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | NT$1.32 Billion | NT$1.41 Billion | NT$578.36 Million | NT$576.62 Million | NT$505.81 Million |
| Net Receivables | NT$514.49 Million | NT$565.57 Million | NT$586.42 Million | NT$585.18 Million | NT$546.25 Million |
| Inventory | NT$303.63 Million | NT$289.73 Million | NT$294.52 Million | NT$227.62 Million | NT$115.65 Million |
| Property, Plant & Equipment | — | — | — | NT$2.21 Billion | NT$1.72 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | NT$1.93 Billion | NT$2.01 Billion | NT$1.79 Billion | NT$1.68 Billion | NT$1.42 Billion |
| Total Current Liabilities | NT$1.03 Billion | NT$1.09 Billion | NT$1.02 Billion | NT$910.38 Million | NT$731.66 Million |
| Long-term Debt | — | — | NT$0.00 | NT$1.32 Million | NT$10.33 Million |
| Net Debt | — | — | NT$-284.28 Million | NT$80.63 Million | NT$233.34 Million |
| Total Stockholder Equity | NT$4.02 Billion | NT$3.62 Billion | NT$3.18 Billion | NT$2.66 Billion | NT$2.19 Billion |
| Retained Earnings | NT$2.31 Billion | NT$2.00 Billion | NT$1.68 Billion | NT$1.28 Billion | NT$912.42 Million |
Universal Vision Biotechnology Co Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Universal Vision Biotechnology Co Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$1.67 Billion | NT$1.67 Billion | NT$1.55 Billion | NT$1.27 Billion | NT$911.77 Million |
| Capital Expenditures | NT$563.82 Million | NT$437.09 Million | NT$474.28 Million | NT$492.83 Million | NT$328.70 Million |
| Free Cash Flow | NT$1.10 Billion | NT$1.23 Billion | NT$1.08 Billion | NT$775.34 Million | NT$583.07 Million |
| Investing Cash Flow | — | — | — | NT$-564.65 Million | NT$-379.81 Million |
| Financing Cash Flow | — | — | NT$-710.65 Million | NT$-539.83 Million | NT$-612.33 Million |
| Dividends Paid | NT$635.44 Million | NT$593.07 Million | NT$479.57 Million | NT$380.62 Million | NT$319.72 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | NT$543.79 Million | NT$521.49 Million | NT$446.15 Million | NT$372.25 Million | NT$319.52 Million |
| Change in Cash | NT$272.38 Million | NT$-555.69 Million | NT$359.53 Million | NT$168.83 Million | NT$-81.81 Million |
Universal Vision Biotechnology Co Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Universal Vision Biotechnology Co Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2026 | 3.00 | 3.70 | -18.87% |
| Mar 05, 2026 | 3.48 | 3.42 | +1.75% |
| Nov 13, 2025 | 4.04 | 3.53 | +14.45% |
| Aug 13, 2025 | 0.50 | 3.33 | -84.99% |
| May 13, 2025 | 4.27 | 3.55 | +20.28% |
| Mar 12, 2025 | 2.80 | 3.09 | -9.31% |
| Nov 13, 2024 | 2.87 | 3.43 | -16.33% |
| Aug 12, 2024 | 3.28 | 3.18 | +3.14% |